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Abstract: Multiple sclerosis (MS) is a devastating and debilitating neurodegenerative disease of
unknown cause. A consensus suggests the involvement of both genetic and environmental factors of
which the latter may involve human exposure to aluminium. There are no data on the content and
distribution of aluminium in human brain tissue in MS. The aluminium content of brain tissue from
14 donors with a diagnosis of MS was determined by transversely heated graphite furnace atomic
absorption spectrometry. The location of aluminium in the brain tissue of two donors was investigated
by aluminium-specific fluorescence microscopy. The aluminium content of brain tissue in MS was
universally high with many tissues bearing concentrations in excess of 10 µg/g dry wt. (10 ppm) and
some exceeding 50 ppm. There were no statistically significant relationships between brain lobes,
donor age or donor gender. Aluminium-specific fluorescence successfully identified aluminium
in brain tissue in both intracellular and extracellular locations. The association of aluminium with
corpora amylacea suggests a role for aluminium in neurodegeneration in MS.
Keywords: multiple sclerosis; human exposure to aluminium; human brain tissue; TH GFAAS;
aluminium-specific fluorescence
1. Introduction
Multiple sclerosis (MS) is a chronic, immune-mediated, demyelinating disease of the central
nervous system of unknown aetiology. Despite some progress, advances in understanding the
pathogenesis of MS remain frustratingly slow [1]. Effective treatments for MS are rare [2,3].
The consensus remains that MS is likely to involve both genetic and environmental factors acting
either in isolation or together in various disease phenotypes. Human exposure to aluminium [4]
is identified as a possible contributor to MS. Individuals with relapsing remitting (RRMS) and
secondary progressive (SPMS) MS were shown to excrete large amounts of aluminium in their urine [5],
an observation recently built upon and confirmed in individuals with SPMS [6]. The origin in the
body of excreted aluminium, identified in aforementioned research, is unknown; although it may be
brain tissue as myelin [7] and oligodendrocytes [8] are specific targets in animal models of aluminium
intoxication. However, while data demonstrate the presence of aluminium in human brain tissue in
neurodegenerative/neurodevelopmental disease [9,10], there are no such data for MS. Herein we have
carried out the first quantitative measurements of aluminium in brain tissue for MS and supported
these data with the first imaging of the location of aluminium in donor tissues.
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2. Materials and Methods
2.1. Tissues
Brain tissues were obtained from the Multiple Sclerosis Society Tissue Bank, Imperial College,
London following ethical approval (NRES Approval No. 08/MRE09/31). Snap-frozen tissue was
obtained from 8 female (39–82 years old) and 6 male (38–66 years old) donors with diagnoses of
primary progressive (2), relapsing progressive (2), secondary progressive (9) or relapsing remitting (1)
MS [11]. Histology slides were provided from 1 female (SPMS) and 1 male (RRMS) donor.
2.2. Quantitative Measurements
The aluminium content of tissues was measured by an established and fully validated method [12]
that herein is described only briefly. Samples of cortex, between 0.6 and 5.0 g in weight, were thawed
at room temperature and cut, using a stainless steel blade, into sections approximately 0.3 g in weight.
Tissues were dried to a constant dry weight in an incubator at 37 ◦C. Dry and weighed tissues were
digested in a microwave (MARS Xpress CEM Microwave Technology Ltd., Buckingham, UK) in a
mixture of 1 mL 15.8 M HNO3 (Fisher Analytical Grade, Loughborough, UK) and 1 mL 30% w/v
H2O2 (BDH Aristar, Poole, UK). The resultant digests were clear with no fatty residues and, upon
cooling, were made up to 5 mL using ultrapure water (cond. < 0.067 µS/cm). Total aluminium was
measured in each sample by transversely heated graphite furnace atomic absorption spectrometry
(TH GFAAS), Perkin-Elmer, Beaconsfield, UK) using matrix-matched standards and an established
analytical programme alongside previously validated quality assurance data including the application
of 174 method blanks to account for issues of extraneous contamination [12].
2.3. Fluorescence Microscopy
Methods are described in full elsewhere [10] and only briefly summarised herein. Chemicals
were purchased from Sigma Aldrich (Poole, UK) unless otherwise stated. The MS Society Brain Bank
provided five 5-µm thick serial paraffin-embedded histology sections of brain tissue from frontal,
parietal, occipital and temporal lobes and hippocampal tissue from two donors, a female with SPMS
and a male with RRMS.
Sections were deparaffinised using Histo-Clear (National Diagnostics, Nottingham,
UK), rehydrated through an ethanol gradient and rinsed thoroughly in ultrapure water
(cond. < 0.067 µS/cm) using standard techniques, prior to staining. Sections were stained for
45 min in a 50 mM PIPES buffer, pH 7.4 for the assessment of tissue autofluorescence or lumogallion
(4-chloro-3-(2,4-dihydroxyphenylazo)-2-hydroxybenzene-1-sulphonic acid, TCI Europe N.V. Belgium),
as has been previously optimised for use in cells [13] and human tissues [14]. Sections were
subsequently washed in 50 mM PIPES buffer, pH 7.4 and rinsed for 30 s in ultrapure water prior to
mounting with Fluoromount™. Fluorescence microscopy was performed using an Olympus BX50
fluorescence microscope equipped with a mercury lamp as the illumination source. Lumogallion
fluorescence was acquired using a U-MNIB3 filter cube (λex: 470–495 nm, DM: 505 nm, λem: 510 nm,
longpass, Olympus, Southend-on-Sea, UK) at a final magnification of ×400. Lumogallion stained
sections were sequentially scanned in the sequence that lumogallion reactive regions were imaged
on adjacent non-stained serial sections. Fluorescence micrographs were obtained using the CellD
software suite (Soft imaging Solutions, SiS, Olympus, GmbH, Münster, Germany) and channels
merged by use of Photoshop (Adobe Systems Inc., Palo Alto, CA, USA). The size and morphology of
cells and their localisation in specific brain regions were considered when assessing the presence of
intracellular aluminium.
2.4. Statistical Analyses
Data for aluminium content of tissues were not normally distributed and being strongly skewed
were log transformed to allow for the use of parametric tests. The median and interquartile
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range were calculated for each donor and additionally per donor and lobe. Non-parametric
correlation analyses between non-transformed aluminium data and parametric correlations using
log-transformed aluminium data and age were performed. Analysis of variance for repeated
measurements (stratified for lobes) was used to detect significant differences between lobes, gender
and age classes. We considered a p-value smaller than 0.05 to be statistically significant. For both
matching and statistical analyses, SPSS Statistics v.22 (IBM Analytics, Armonk, NY, USA) was used.
All statistical analyses were done with SPSS.
3. Results
3.1. Aluminium Content of Brain Tissues
The aluminium content of all tissues ranged from 0.01 (the limit of quantitation) to values in
excess of 50 µg/g dry wt. (Supplementary Tables). Where tissues were available for all four main lobes,
the aluminium content (Mean ± SD) for whole brains was 6.94 ± 13.75 (MS107), 6.38 ± 23.56 (MS274),
1.55 ± 2.06 (MS356) and 3.32 ± 6.37 µg/g dry wt. (MS401) (Table 1). Detailed statistical analyses
(see Section 2.4) of raw and transformed data have not revealed any statistically significant differences
between the aluminium content of different lobes in relation to either gender or age of the donor.
Table 1. Brain aluminium content (µg/g dry wt. mean (SD) (n)) for each lobe of each MS
donor. NA—tissue unavailable; PPMS—primary progressive MS; RPMS—relapsing progressive MS;
SPMS—secondary progressive MS; RRMS—relapsing remitting MS.
Donor Id. Gender Age MS Frontal Temporal Occipital Parietal
MS307 Male 55 PPMS 1.75(0.91) (5) 0.46(0.60) (13) NA 1.76(1.28) (6)
MS107 Male 38 RPMS 3.41(3.54) (5) 0.59(0.64) (3) 0.58(0.04) (2) 9.84(16.70) (17)
MS245 Male 64 SPMS 2.86(0.80) (4) NA NA NA
MS274 Male 56 RRMS 29.14(57.92) (5) 3.53(2.55) (13) 0.50(0.57) (10) 0.36(0.20) (3)
MS304 Male 52 SPMS 1.82(1.40) (5) NA 3.98(9.84) (28) NA
MS313 Male 66 PPMS 0.47(0.63) (5) NA 3.64(4.41) (20) 1.28(3.22) (20)
MS330 Female 59 SPMS 2.02(1.64) (5) NA NA NA
MS317 Female 48 SPMS 5.44(5.73) (5) NA NA NA
MS356 Female 45 SPMS 1.84(2.85) (5) 1.81(1.78) (5) 1.40(1.86) (16) 1.51(2.44) (8)
MS401 Female 82 SPMS 0.65(0.65) (4) 1.55(1.96) (16) 5.66(9.27) (20) 2.36(1.65) (8)
MS180 Female 44 SPMS 3.34(3.71) (5) NA NA NA
MS114 Female 52 SPMS 1.68(1.25) (5) 3.45(4.38) (17) NA 0.59(0.55) (6)
MS203 Female 53 SPMS 2.39(1.34) (5) 0.81(0.41) (7) NA 3.31(4.00) (2)
MS234 Female 39 RPMS 6.35(8.27) (5) NA 0.74(0.50) (5) 2.79(2.83) (19)
Previous measurements of brain aluminium content in our laboratory, using identical analytical
methods, have allowed us to define loose categories of brain aluminium content beginning with
≤1.00 µg/g dry wt. as pathologically benign (as opposed to ‘normal’). Approximately 42% of
tissues (141/332) fitted this category while about 33% of tissues (108/332) had an aluminium content
considered as pathologically concerning (≥2.00 µg/g dry wt.). Almost 80% of these pathologically
concerning tissues (83/108) had an aluminium content considered as pathologically significant
(≥3.00 µg/g dry wt.). Every individual had at least one tissue with a pathologically significant content
of aluminium (Supplementary Tables). The brains of 11 individuals had at least one tissue with an
aluminium content ≥ 5.00 µg/g dry wt. while seven of these donors had at least one tissue with an
aluminium content ≥ 10.00 µg/g dry wt. (Supplementary Tables).
3.2. Aluminium Fluorescence in Brain Tissues
Aluminium was successfully identified in brain tissue of both donors by aluminium-specific
fluorescence microscopy. Significant extracellular accumulations of aluminium were found in
association with small blood vessels in the white matter of the frontal lobe of a male donor with
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RRMS (Figure 1a). Lipofuscin is a granular, ageing-associated, lipid-rich pigment that predominantly
accumulates intraneuronally in brain tissue as a product of lysosomal degradation [9]. Herein,
lipofuscin deposits were identified across all MS donor tissues via fluorescence microscopy, appearing
as an autofluorescent yellow pigment in both lumogallion and non-stained tissue sections (Figure 1a).
Autofluorescence imaging of a serial section of tissue confirmed the deposits as aluminium (Figure 1c).
Extracellular aluminium was also identified in the parahippocampal gyrus of the same donor
(Figure 1b) and was again confirmed by autofluorescence of a serial section (Figure 1d). Intracellular
deposits of aluminium, possibly associated with microglia-like cells, were also identified in the
temporal lobe (Figure 2a) and hippocampus (Figure 2b) of the same donor with these clear
lumogallion-reactive accumulations of aluminium being confirmed by autofluorescence of serial
tissue sections (Figure 2c,d). Strong aluminium fluorescence was observed associated with refractile
corpora amylacea-like structures in the frontal cortex of a female donor with SPMS (Figure 3a). While
strong orange fluorescence confirmed the presence of aluminium, light green autofluorescence from
this structure was probably indicative of its refractile nature (Figure 3c). The parahippocampal gyrus
of the same donor showed numerous intracellular deposits of aluminium and especially associated
with glial, perhaps astrocyte-like cells (Figure 3b). Autofluorescence of a serial section confirmed
the presence of aluminium in this tissue (Figure 3d). Diffuse extracellular deposits of aluminium,
up to 50 µm across, were identified in the basal ganglia of the male donor with RRMS (Figure 4a)
and autofluorescence confirmed its presence as aluminium (Figure 4c). Other unusual extracellular
(or possibly intraneuronal) deposits of aluminium were identified in the medial temporal region of the
female donor with SPMS (Figure 4b) and the presence of aluminium was confirmed by autofluorescence
(Figure 4d). Many areas of brain tissue from both donors showed no positive staining for aluminium
(Supplementary Figure S1).
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Figure 1. Extracellular aluminium in the frontal lobe and hippocampus of a 56-year-old male donor 
(MS274), diagnosed with RRMS. (a) Intense orange fluorescence (white arrow) indicating punctate 
deposits of aluminium was observed in the perivascular region of a small blood vessel in the white 
matter of the frontal lobe, in close proximity to lipofuscin, identified by yellow fluorescence. (b) 
Extracellular deposits of aluminium, identified as diffuse orange-red fluorescence, appear co-
deposited with lipofuscin (white arrow) in white matter adjacent to the parahippocampal gyrus. (c,d) 
Autofluorescence of serial sections confirms the identity of aluminium in (a,b) respectively. Upper 
and lower panels depict magnified inserts of the fluorescence channel and bright field overlay. 
Magnification ×400, scale bars: 50 μm. 
Figure 1. Extracellular aluminium in the frontal lobe and hippocampus of a 56-year-old male
donor (MS274), diagnosed with RRMS. (a) Intense orange fluorescence (white arrow) indicating
punctate deposits of aluminium was observed in the perivascular region of a small blood vessel
in the white matter of the frontal lobe, in close proximity to lipofuscin, identified by yellow
fluorescence. (b) Extracellular deposits of aluminium, identified as diffuse orange-red fluorescence,
appear co-deposited with lipofuscin ( hite arrow) in white matter adjacent to the parahippocampal
gyrus. (c,d) Autofluorescence of serial sections confirms the identity of aluminium in (a,b) respectively.
Upper and lower panels depict magnified inserts of the fluorescence channel and bright field overlay.
Magnification ×400, scale bars: 50 µ .
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Figure 3. Aluminium in the frontal lobe and hippocampus of a 48-year-old female donor (MS317), 
diagnosed with SPMS. (a) Intense orange aluminium fluorescence was identified in refractile corpora 
amylacea (or mineralised deposits) in the frontal cortex (grey matter). (b) Intracellular aluminium was 
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Figure 2. Intracellular alu inium in glia observed in the temporal lobe and hippocampus of a
56-year-old male donor (MS274), diagnosed with RRMS. Bright orange fluorescence was observed
intracellularly and co-deposited within the cellular debris of occasional cells morphologically
compatible with glial cells in (a) the internal capsule and (b) the hippocampus (both grey matter).
Autofluorescence of serial sections (c,d) confirms the identity of aluminium in (a,b) respectively.
Upper and lower panels depict magnified inserts of the fluorescence channel and bright field overlay.
Magnification ×400, scale bars: 50 µm.
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Figure 3. Aluminium in the frontal lobe and hippocampus of a 48-year-old female donor (MS317), 
diagnosed with SPMS. (a) Intense orange aluminium fluorescence was identified in refractile corpora 
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Figure 3. Aluminiu in the frontal lobe and hippoca pus of a 48-year-old female donor (MS317),
diagnosed ith SP S. (a) Intense orange aluminium fluorescence was identified in refractile
corpora amylacea (or mineralised deposits) in the frontal cortex (grey matter). (b) Intracellular
aluminium was also observed in occasional glial-like cells in the parahippocampal gyrus (white matter).
Autofluorescence of serial sections (c,d) confirms the identity of aluminium in (a,b) respectively.
Upper and lower panels depict magnified inserts of the fluorescence channel and bright field overlay.
Magnification ×400, scale bars: 50 µm.
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the fluorescence channel and bright field overlay. Magnification ×400, scale bars: 50 μm. 
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female (MS317) donor (Figures 1–4). In both of these donors the lobes, specifically frontal and temporal,
where aluminium was shown to be high by TH GFAAS (Table 1), also showed many more deposits of
aluminium by fluorescence. Aluminium was found in both extracellular and intracellular locations and
in both grey and white matter. It as difficult to associate the aluminium with any known pathologies
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specific to MS though aluminium was found in diffuse, perhaps plaque-like structures (Figure 4),
glial-like cells, as well as in corpora amylacea (Figure 3). The latter was of particular interest since
corpora amylacea are possible tombstones of neurodegeneration and in MS could be remnants of both
neuronal and non-neuronal cell death [18,19]. Aluminium was located throughout the hippocampus
of both donors (Figures 1 and 3) tissues, which were not made available for quantitative analyses. It is
important to stress that large areas of all tissues studied for these donors did not show any positive
aluminium-specific fluorescence (Supplementary Figure S1).
5. Conclusions
We have investigated the aluminium content of brain tissue in MS and shown the aluminium
content to be elevated and associated with the condition including neurodegeneration. Aluminium may
contribute towards the aetiology of MS and recent research demonstrating the efficacy of silicon-rich
mineral waters in increasing the urinary excretion of aluminium [6] may represent a therapeutic
strategy for individuals with MS.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-4601/15/8/1777/
s1, Figure S1: Representative negative lumogallion staining of white and grey matter of the occipital lobe of a
56-year-old male donor (MS274), diagnosed with RRMS. T, Tables S1: MS307 (Male, 55 PPMS), Table S2: MS107
(Male, 38 RPMS), Table S3: MS245 (Male, 64 SPMS), Table S4: MS274 (Male, 56 RRMS), Table S5: MS330 (Female, 59
SPMS), Table S6: MS317 (Female, 48 SPMS), Table S7: MS304 (Male, 52 SPMS), Table S8: MS356 (Female, 45 SPMS),
Table S9: MS401 (Female, 82 SPMS), Table S10: MS180 (Female, 44 SPMS), Table S11: MS313 (Male, 66 PPMS),
Table S12: MS114 (Female, 52 SPMS), Table S13: MS203 (Female, 53 SPMS), Table S14: MS234 (Female 39, RPMS).
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